We are live on ! Find out more
CDMO

Avid Bioservices, Inc. Common Stock

Delisted

CDMO was delisted on the 4th of February, 2025.

171 hedge funds and large institutions have $465M invested in Avid Bioservices, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 62 increasing their positions, 56 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 19

11% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 56

6% more capital invested

Capital invested by funds: $437M → $465M (+$27.8M)

3% more funds holding

Funds holding: 166171 (+5)

76% less call options, than puts

Call options by funds: $313K | Put options by funds: $1.3M

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
171
Holders Change
+5
Holders Change %
+3.01%
% of All Funds
2.47%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
25
Increased
62
Reduced
56
Closed
19
Calls
$313K
Puts
$1.3M
Net Calls
-$987K
Net Calls Change
-$2.43M
Name Holding Trade Value Shares
Change
Change in
Stake
Marshall Wace
51
Marshall Wace
United Kingdom
$1.4M +$1.5M +195,461 New
Rafferty Asset Management
52
Rafferty Asset Management
New York
$1.32M -$2.61M -341,285 -65%
MAG
53
Millrace Asset Group
Pennsylvania
$1.31M +$1.4M +183,464 New
UBS Group
54
UBS Group
Switzerland
$1.27M -$1.14M -149,195 -46%
DM
55
Deerfield Management
New York
$1.26M +$572K +74,797 +73%
UBS AM
56
UBS AM
Illinois
$1.17M +$791K +103,435 +171%
SEI Investments
57
SEI Investments
Pennsylvania
$1.14M +$159K +20,766 +15%
CCM
58
Cinctive Capital Management
New York
$1.09M +$455K +59,467 +64%
QOP
59
Quinn Opportunity Partners
Virginia
$1.06M -$68.8K -9,000 -6%
BFM
60
Boothbay Fund Management
New York
$1.02M -$1.86M -242,633 -63%
HF
61
HRT Financial
New York
$904K +$969K +126,701 New
Swiss National Bank
62
Swiss National Bank
Switzerland
$888K
BNP Paribas Financial Markets
63
BNP Paribas Financial Markets
France
$876K -$1.44M -187,931 -61%
JF
64
Jump Financial
Illinois
$858K -$457K -59,775 -33%
M&T Bank
65
M&T Bank
New York
$739K -$643 -84 -0.1%
AI
66
Atom Investors
Texas
$724K +$776K +101,443 New
IECM
67
Intrinsic Edge Capital Management
Illinois
$714K +$765K +100,000 New
RhumbLine Advisers
68
RhumbLine Advisers
Massachusetts
$676K +$41.4K +5,408 +6%
Invesco
69
Invesco
Georgia
$666K +$226K +29,486 +46%
LPL Financial
70
LPL Financial
California
$644K -$2.01K -263 -0.3%
Mariner
71
Mariner
Kansas
$621K
GLA
72
Great Lakes Advisors
Illinois
$619K +$163K +21,370 +33%
ZB
73
Zions Bancorporation
Utah
$601K -$17.7K -2,314 -3%
AFM
74
Anson Funds Management
Texas
$555K -$662K -86,525 -53%
GCP
75
GSA Capital Partners
United Kingdom
$554K -$115K -15,098 -16%

CDMO Hedge Fund Activity: Q2 2024 in Review

171 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Avid Bioservices, Inc. Common Stock (CDMO) for Q2 2024, worth a combined $465M — up 6.4% from $437M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new CDMO positions and 19 closed out — a net gain of 6 holders — while 62 added to existing stakes and 56 trimmed.

The largest buyer was Coliseum Capital Management, opening a new position worth an estimated $13.4M. The largest seller was State Street, cutting an estimated $19.2M.

  • 171 institutional investors held Avid Bioservices, Inc. Common Stock (CDMO) as of Q2 2024, up from 166 in Q1 2024.
  • Funds reported $465M of Avid Bioservices, Inc. Common Stock stock for Q2 2024, up 6.4% quarter-over-quarter.
  • 25 funds opened new Avid Bioservices, Inc. Common Stock positions in Q2 2024 and 19 closed out, a net change of +6 holders.
  • The largest Avid Bioservices, Inc. Common Stock buyer in Q2 2024 was Coliseum Capital Management, an estimated $13.4M added.
  • The largest Avid Bioservices, Inc. Common Stock seller in Q2 2024 was State Street, an estimated $19.2M sold.

Based on aggregated 13F filings for Q2 2024.